The question asked by Robert LeBoyer from Roth Capital on the recent conference call is very important because it seems that the KEM analysis is further indication that heretofore the focus for treatment of AD has been on the wrong gene (ApoE4) or factors (APP factors) and that we are on the correct path. If the KEM analysis has validity, and I think it does, this question and the answer should attract much attention. Anavex remains a speculative investment, but with the KEM analysis this stock is not as speculative as it once was. We have come a long way. Perhaps there is light at the end of the tunnel? Here is the Q & A:
"Operator
Our next question comes from Robert LeBoyer from Roth Capital Partners. Robert, your line is now open.
Robert LeBoyer
Thank you and congratulations for on all of this progress. The question I have is related to the genomic studies. And the description that you just gave, Christopher, was very thorough and complete. The only other questions I would have on top of those things were whether you found any other correlations with other genes that have been associated with Alzheimer's such as ApoE4 or presenilin or any of the APP processing factors that have been preliminarily tied to Alzheimer's or if there’s any kind of information there?
Christopher Missling
Very good question and obviously the KEM analysis is exactly meant to find if there is a correlation to identify such a correlation. And we did not find any one for ApoE4 predominant genes are not – and I think the way to explain this is that the ApoE4 seemed to be indicating a risk factor of the Alzheimer's pathology.
So it is a correlation with the fact that you will likely become pathologic with Alzheimer's disease. But what we're looking at is the response with our drug. And the good news is that independently if you have ApoE4 gene carrying or if you do not have that gene – only have ApoE3 or ApoE2 that seem to be indicate you will have the same beneficial effect of the drug treatment independently of the fact that if you are likely getting Alzheimer's disease or not. So the drug seems to be responding in the same way independently of any risk factors of getting Alzheimer's disease in the first place. And that is right now our current understanding based on the analysis.
Robert LeBoyer
Okay, great. That's an important point. Thank you very much.
Christopher Missling
Thank you.”
